What are the treatments for colon cancer at Iveca?

The first of immune cells refers to the separation of the patient's cells from the blood, and some cytokines are used in vitro to make it become a killer cell, and then transfused back into the blood, which can recognize tumor cells for killing. Immunity refers to the method of artificially enhancing or inhibiting the body's immune function to achieve the purpose of disease in response to the body's low or hyperactive immune state. The immune and anti-cancer drug "Iveka" is an innovative immune macromolecule drug developed by relying on the Pickup Immune Technology Platform, which is a first-class first-class biological product, which is also the third macromolecular immune biological product launched by the Pickup Immune Technology Platform to enter the clinical development stage.

Iveka Immunity**! It is the system by which the human body recognizes antigenic substances and processes anti-derived substances. The common immune cells in the human body are self-divided into T cells and self-B cells.

In the process of tumor recognition and killing, the body's T cells play a major role. The principle is that there are PD-1 receptors and PD-L1 ligands on the surface of tumor cells, and the combination of PD1 and PD-L1 from the cells has evaded the recognition and killing of normal T cells, while immunodrugs are combined with PD-1 receptors and ligands to re-expose tumor cells to the recognition and killing range of T cells

Immunity**yivyka (ivecar) adopts the method of cellular immune activation on the body to spontaneously produce a large number of T cells and macrophages, thereby killing tumor cells, the method is to first correct and then remove evil, which can safely and effectively improve the best effect of tumor patients, improve the quality of life, and truly extend the life of patients!

According to the results of preclinical studies, YivykaTM (Ivecar) has a more attractive broad spectrum in anti-solid tumors. The product has shown excellent efficacy in solid tumors** such as breast cancer, lung cancer, liver cancer, pancreatic cancer, colon cancer, prostate cancer, bladder cancer, kidney cancer, and lymphoma, and its tumor inhibition effect is not inferior to or even better than that of first-line chemotherapy drugs, targeted drugs and immune efficacy drugs; When combined, immune** combined use shows a stronger** effect.

Iveka Immunity** is the system by which the human body recognizes antigenic substances and processes them. The most common immune cells in the human body are T cells and B cells. In the process of tumor identification and killing, the body's T cells play a major role.

The current immunity is based on this principle, which is that there are PD-1 receptors and PD-L1 ligands on the surface of tumor cells, and the combination of PD1 and PD-L1 from the cells evades the recognition and killing of normal T cells, while immune drugs are combined with PD-1 receptors and ligands to re-expose tumor cells to the recognition and killing range of T cells, which plays a leading role

In addition, because the method of biological immunity to cancer is actually very high, that is, it is possible that it cannot be completely controlled after the meeting, which leaves a certain internal hidden danger for cancer. The immune and anti-cancer drug "Iveka" is an innovative immune macromolecule drug developed by relying on the Pickup Immune Technology Platform, which is a class of biological products for the treatment of hunger, and this brigade is also the third macromolecular immune biological product launched by the Pickup Immune Technology Platform to enter the clinical development stage. **Somewhat cheaper than other products.

The current problem is that there is breast cancer, and the patient's mental condition is not very good, and the physical state is not very good The current situation should first clarify the pathological stage of breast cancer, and determine whether it can be surgically operated and drug chemotherapy can be combined with clinical practice after surgery. It is suggested that the current situation is best to go to the local cancer hospital at or above the provincial level, and the choice of principles is best to listen to the advice of experts and professors.

In recent years, poly (ADP-ribose) polymerase inhibitors (PARP inhibitors) have shown significant effects as anti-cancer agents in female breast and ovarian cancers caused by BRCA1 or BRCA2 deletion. PARP inhibitors are thought to work by blocking the DNA repair function of PARP family proteins, thereby promoting cancer cell death.

YivykaTM (iveka) adopts the method of cellular immune activation** acting on the body to spontaneously produce a large number of T cells and macrophages, thereby killing tumor cells

Yes, it's really good, leading the way in immuno-oncology**.